Randomized comparison of interferon-alpha vs chemotherapy in patients with Philadelphia-negative chronic myelogenous leukemia (CML).

被引：0
|
作者：
Hochhaus, A [1 ]
Hehlmann, R [1 ]
Bartram, CR [1 ]
Heimpel, H [1 ]
Reiter, A [1 ]
Berger, U [1 ]
Ansari, H [1 ]
Skladny, H [1 ]
Heinze, B [1 ]
Hossfeld, DK [1 ]
机构：
[1] UNIV HEIDELBERG,KLINIKUM MANNHEIM,GERMAN CML STUDY GRP,MED KLIN 3,MANNHEIM,GERMANY
来源：
BLOOD | 1997年 / 90卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2298 / 2298
页数：1
相关论文
共 50 条
  • [41] PHILADELPHIA-NEGATIVE CHRONIC MYELOPROLIFERATIVE DISORDERS - ROLE OF INTERFERON ALPHA 2-A
    Raza, K.
    Chonfhaola, A. Ni
    McCloy, M.
    Sergeant, J.
    Murphy, P.
    Thornton, P.
    Quinn, J.
    HAEMATOLOGICA, 2014, 99 : 672 - 672
  • [42] Multiple sclerosis associated with interferon-alpha therapy for chronic myelogenous leukemia
    Kataoka, I
    Shinagawa, K
    Shiro, Y
    Okamoto, S
    Watanabe, R
    Mori, T
    Ito, D
    Harada, M
    AMERICAN JOURNAL OF HEMATOLOGY, 2002, 70 (02) : 149 - 153
  • [43] Results of therapy with interferon alpha and cyclic combination chemotherapy in patients with Philadelphia chromosome positive chronic myelogenous leukemia in early chronic phase
    Giles, FJ
    Kantarjian, H
    O'Brien, S
    Rios, MB
    Cortes, J
    Beran, M
    Koller, C
    Keating, M
    Talpaz, M
    LEUKEMIA & LYMPHOMA, 2001, 41 (3-4) : 309 - 319
  • [44] Follow-up of nonclonal hematopoetic progenitor cells in the peripheral blood of interferon-alpha treated patients with chronic myelogenous leukemia (CML).
    Sick, C
    Schultheis, B
    Pasternak, G
    Heissig, B
    Hehlmann, R
    BLOOD, 1997, 90 (10) : 4016 - 4016
  • [45] INTERFERON-ALPHA RESTORES NORMAL NEGATIVE REGULATION OF CHRONIC MYELOGENOUS LEUKEMIA PROGENITOR PROLIFERATION BY THE MARROW MICROENVIRONMENT
    BHATIA, R
    VERFAILLIE, CM
    BLOOD, 1994, 84 (10) : A517 - A517
  • [46] Imatinib and beyond - the new CML study IV - A randomized controlled comparison of imatinib vs imatinib/interferon-alpha vs imatinib/low-dose AraC vs imatinib after interferon-alpha failure in newly diagnosed chronic phase chronic myeloid leukemia
    Berger, U
    Engelich, G
    Reiter, A
    Hochhaus, A
    Hehlmann, R
    ANNALS OF HEMATOLOGY, 2004, 83 (04) : 258 - 264
  • [47] Imatinib and beyond—the new CML study IVA randomized controlled comparison of imatinib vs imatinib/interferon-alpha vs imatinib/low-dose AraC vs imatinib after interferon-alpha failure in newly diagnosed chronic phase chronic myeloid leukemia
    U. Berger
    G. Engelich
    A. Reiter
    A. Hochhaus
    R. Hehlmann
    Annals of Hematology, 2004, 83 : 258 - 264
  • [48] Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia
    P Mittal
    R M Saliba
    S A Giralt
    M Shahjahan
    A I Cohen
    S Karandish
    F Onida
    M Beran
    R E Champlin
    M de Lima
    Bone Marrow Transplantation, 2004, 33 : 1005 - 1009
  • [49] Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia
    Mittal, P
    Saliba, RM
    Giralt, SA
    Shahjahan, M
    Cohen, AI
    Karandish, S
    Onida, F
    Beran, M
    Champlin, RE
    de Lima, M
    BONE MARROW TRANSPLANTATION, 2004, 33 (10) : 1005 - 1009
  • [50] Complex philadelphia (PH) translocations in 7 patients with chronic myelogenous leukemia (CML)
    Grau, J.
    Vall-Llovera, F.
    Hermosilla, A.
    Granada, I.
    Xiville, N. Ruiz
    Xandri, M.
    Zamora, L.
    Cabezon, M.
    Milla, F.
    Feliu, E.
    CHROMOSOME RESEARCH, 2007, 15 : 192 - 193
12345